Percutaneous glucose monitoring system

Abstract

The invention discloses a percutaneous glucose monitoring system, and relates to the technical field of medical detection, and the system comprises a continuous glucose monitoring device used for monitoring the glucose concentration of subcutaneous interstitial fluid of a patient; the patient user side is used for acquiring the information of the continuous glucose monitoring equipment, receiving the glucose concentration data and displaying the warm-up progress of the continuous glucose monitoring equipment; and the cloud server is used for completing data sharing and data reading authorization. According to the invention, the patient user side pays attention to the warm-up time of the continuous glucose monitoring equipment and carries out forward visual display on the warm-up time, and visual management of glucose monitoring data analysis is carried out, so that the convenience of glucose monitoring is improved. In addition, the system supports second monitoring equipment, so that relatives and friends can know the glucose monitoring state of the patient in time, the glucose fluctuation reason is speculated, and the glucose control effect is further improved.

Description

Technical Field

[0001] The present invention relates to the field of medical detection technology, and more particularly to a transcutaneous glucose monitoring system. Background Art

[0002] Diabetes is a systemic metabolic disorder, often accompanied by abnormal fat and protein metabolism. Long-term high blood sugar can cause common complications such as retinopathy, diabetic nephropathy, and diabetic foot. Blood sugar monitoring is of great significance to diabetic patients. Correct blood sugar monitoring is not only conducive to diabetes management and monitoring, but also helps evaluate the effectiveness of treatment and participate in the adjustment of diet, exercise and drug regimens.

[0003] Daily blood sugar monitoring generally uses venous blood sugar monitoring and fingertip blood sugar monitoring. Among them, venous blood sugar monitoring can detect fasting blood sugar and blood sugar two hours after a meal, and understand the blood sugar control situation in the past three months; while fingertip blood sugar monitoring can help diabetic patients monitor blood sugar at any time. With the emergence of dynamic blood sugar monitoring, patients can monitor the glucose concentration of the interstitial fluid of the subcutaneous tissue through a glucose sensor to indirectly reflect the blood sugar level, draw a blood sugar change curve, provide continuous, comprehensive and reliable blood sugar information throughout the day, and find high blood sugar and low blood sugar that are not easily detected by traditional monitoring methods.

[0004] The common continuous glucose monitoring system (CGM system) currently available on the market for monitoring the patient's blood sugar / glucose concentration (level) includes a sensor and a transmitter. After the sensor is implanted subcutaneously, it senses the physiological signals in the tissue fluid, transmits the physiological signals to the transmitter, and can issue an alarm when the physiological signals are abnormal. However, before the sensor can measure correctly, the sensor must be completely "wet" or hydrated (wetting) to achieve equilibrium with the glucose in the patient's body. Therefore, after the sensor is implanted subcutaneously, before the sensor starts measuring, a warm-up period must be waited for the patient / user to read an accurate reading of the glucose concentration. The existing continuous glucose monitoring system has not fully considered the intuitive display of the device's warm-up time in terms of the graphical user interface (GUI) and navigation process on the patient user side, and the existing system is still insufficient in improving the blood sugar control effect, and it is difficult to quickly understand the reasons for the blood sugar fluctuations of family members. To solve this problem, a more intuitive navigation design will help users interpret the analyte measurement results more accurately, which is also an important issue that needs to be solved in this technical field. Summary of the invention

[0005] In view of this, the present invention provides a transcutaneous glucose monitoring system to solve the problems existing in the background technology.

[0006] In order to achieve the above object, the present invention provides the following technical solutions:

[0007] A transcutaneous glucose monitoring system, comprising:

[0008] Continuous glucose monitoring (CGM) devices, which are used to monitor the glucose concentration in the patient's subcutaneous interstitial fluid;

[0009] The patient user terminal is used to obtain continuous glucose monitoring device information, receive glucose concentration data, and display the warm-up progress of the continuous glucose monitoring device;

[0010] Cloud server, used to complete data sharing and authorization to read data;

[0011] Among them, the user interface of the patient client includes:

[0012] The top information area is used to provide the remaining days of use of the current continuous glucose monitoring device, real-time glucose values ​​and trend icons, and indicate the glucose status through color changes or icons;

[0013] Glucose change chart area, used to graphically present the glucose change trend over the past few hours;

[0014] The daily monitoring record overview chart area is used to display the patient's daily glucose trend overview for the past few days;

[0015] The TIR distribution chart area is used to provide statistics on glucose management, showing the proportion of time the patient is within the target glucose range and visualizing the temporal distribution of glucose levels through a color bar graph;

[0016] The bottom navigation bar is used to provide multiple function buttons to allow patients to quickly access different functions of the application.

[0017] In the above transcutaneous glucose monitoring system, optionally, the continuous glucose monitoring device includes:

[0018] A glucose sensor is implanted under the patient's skin to monitor the glucose concentration in the patient's subcutaneous interstitial fluid;

[0019] Temperature sensor, used to monitor ambient temperature;

[0020] A glucose measuring unit, used for applying voltage to the glucose sensor to measure the glucose concentration;

[0021] Batteries, for power supply;

[0022] Wireless communication unit for data transmission.

[0023] In the above transcutaneous glucose monitoring system, optionally, the patient user terminal includes:

[0024] User interface, used to provide warm-up status display, glucose data display and report analysis functions;

[0025] A wireless communication module, used for receiving glucose concentration data transmitted by a continuous glucose monitoring device;

[0026] a memory for storing glucose concentration data, trend analysis, patient health records, and calibration data;

[0027] One or more processors for executing various functional instructions;

[0028] A warm-up control unit, used for providing the warm-up progress and completion time of the continuous glucose monitoring device through a processor;

[0029] The glucose data processing unit is used to continuously receive and process glucose concentration data through one or more processors after the warm-up is completed, and generate real-time glucose readings, dynamic glucose fluctuation curves and glucose management reports.

[0030] In the above transcutaneous glucose monitoring system, optionally, the warm-up control unit includes:

[0031] A time setting module, configured to cause one or more processors to provide a warm-up plan completion time for the continuous glucose monitoring device according to a preset warm-up time;

[0032] A response module, configured to enable one or more processors to detect a power-on action of the continuous glucose monitoring device and respond;

[0033] The time recording module is used to enable one or more processors to record the power-on time and warm-up time of the continuous glucose monitoring device.

[0034] In the above transcutaneous glucose monitoring system, optionally, the warm-up control unit includes:

[0035] A power check module, used to monitor the remaining power of the continuous glucose monitoring device and the patient user end and compare it with the preset startup threshold to determine whether to perform the startup and warm-up procedures;

[0036] The time setting module is used to enable one or more processors to provide a warm-up plan completion time for the continuous glucose monitoring device according to a preset warm-up time.

[0037] The above transcutaneous glucose monitoring system, optionally, the patient user end includes:

[0038] The note module is used by patients to record medication, diet and exercise conditions, and obtain the patient's user information based on the log records;

[0039] A warm-up progress display module, used to display the warm-up progress of the continuous glucose monitoring device;

[0040] The glucose display module is used to display the current glucose concentration data and glucose value fluctuations through different types of trend icons in a block-like design.

[0041] In the above transcutaneous glucose monitoring system, optionally, the warm-up progress display module may display the warm-up time and / or the warm-up plan completion time.

[0042] The above-mentioned transcutaneous glucose monitoring system, the patient user end further includes a calibration unit, and optionally, the calibration unit includes:

[0043] The blood sugar data collection module is used to receive the blood sugar value after the patient has tested it with a blood sugar tester, which is input by the patient himself or automatically transmitted to the patient user terminal;

[0044] A judgment module is used to analyze the validity of blood glucose data and confirm whether the continuous glucose monitoring device is operating normally;

[0045] The correction module is used to write the blood glucose data into the patient user terminal when the blood glucose data is valid and the continuous glucose monitoring device is operating normally.

[0046] In the above transcutaneous glucose monitoring system, optionally, the patient user terminal further includes:

[0047] A drawing module, used to draw glucose curves and perform TIR index statistics based on the patient's glucose concentration data;

[0048] An adjustment module, used to correct the glucose curve and TIR index according to the glucose concentration data;

[0049] The generation module is used to generate continuous glucose monitoring standard reports and dynamic glucose graph reports for glucose concentration data.

[0050] In the above-mentioned transcutaneous glucose monitoring system, optionally, the glucose curve includes: a single-day glucose curve graph, a multi-day continuous glucose monitoring thumbnail graph and a multi-day quartile graph.

[0051] In the above-mentioned transcutaneous glucose monitoring system, optionally, the glucose curve and the TIR index graph display the patient's glucose status by different colors.

[0052] In the above-mentioned transcutaneous glucose monitoring system, optionally, the patient user terminal also includes an alarm module for sending an alarm message to the patient user terminal when the patient's glucose value deviates from the healthy glucose value range.

[0053] A transcutaneous glucose monitoring system, comprising:

[0054] A partnership establishment module is used to scan the barcode information associated with the continuous glucose monitoring device through a camera for authorization, or send an invitation link to the patient user end through a third-party platform to complete the authentication and authorization of the patient's identity and the partner's identity;

[0055] The partner user end queries glucose concentration data and the patient's basic information, glucose monitoring instructions, medication instructions, and consultation instructions based on the patient's authorization.

[0056] In the above transcutaneous glucose monitoring system, optionally, the partner user terminal includes:

[0057] Early warning module, used to understand the glucose fluctuations of multiple partners and take effective measures in time;

[0058] An update module is used to prioritize the glucose monitoring status of a partner that is updated in real time;

[0059] Glucose display module, used to obtain the current glucose monitoring status of multiple partners and infer the cause of fluctuations through glucose change trends;

[0060] The blood glucose display module is used to obtain the latest blood glucose test records.

[0061] In the above-mentioned transcutaneous glucose monitoring system, optionally, the partner user terminal also includes a note classification module for recording abnormal glucose events and occurrence time, marking abnormal glucose ranges, and converting the marked content to a timeline to compare glucose fluctuations and further infer the cause of glucose fluctuations.

[0062] The above transcutaneous glucose monitoring system, optionally, the partner user terminal includes a glycated hemoglobin display module, which is used to correspond the patient's glycated hemoglobin value to the color bar graph, so as to directly confirm the specific section where the patient's glycated hemoglobin result is located in the common standard system.

[0063] It can be seen from the above technical solution that compared with the prior art, the present invention discloses a transcutaneous glucose monitoring system, which pays attention to the warm-up time of the continuous glucose monitoring equipment and performs a positive and intuitive display, and provides patients with the right to perform background correction through blood glucose data. It can help patients' families to timely understand the glucose monitoring status of their family members, infer the reasons for glucose fluctuations, and help with subsequent disease diagnosis and treatment, further improving the glucose control effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0064] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.

[0065] Figure 1 A schematic diagram of the composition of the transcutaneous glucose monitoring system provided in Example 1;

[0066] Figure 2 A schematic diagram of the composition of the continuous glucose monitoring device provided in Example 1;

[0067] Figure 3 A schematic diagram of the composition of the patient user terminal provided in Example 1;

[0068] Figure 4 A schematic diagram of the composition of a warm-up control unit provided in Example 1;

[0069] Figure 5 A schematic diagram of the use of the annotation module provided in Example 1;

[0070] Figure 6 This is a diagram showing the interface of the patient user terminal provided in Example 1;

[0071] Figure 7 The display mode of the warm-up progress display module provided in the first embodiment;

[0072] Figure 8 A structural diagram of a correction unit provided in Embodiment 1;

[0073] Fig. 9 A structural diagram of a cloud server provided in Example 1;

[0074] Fig.10 A structural diagram of a transcutaneous glucose monitoring system provided in Example 2;

[0075] Fig.11 This is a diagram showing the interface of the partner user terminal provided in Example 2;

[0076] Fig.12 Another interface display diagram of the partner user terminal provided in the second embodiment;

[0077] Fig.13 This is an interface diagram of the glycated hemoglobin display module provided in Example 2. DETAILED DESCRIPTION

[0078] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0079] Embodiment 1

[0080] The embodiment of the present invention discloses a transcutaneous glucose monitoring system 1, such as Figure 1 As shown, including:

[0081] A continuous glucose monitoring device 2, used to monitor the glucose concentration of the patient's subcutaneous interstitial fluid;

[0082] The patient user terminal 3 is used to obtain the continuous glucose monitoring device information, receive the glucose concentration data, and display the warm-up progress of the continuous glucose monitoring device 2;

[0083] The cloud server 4 is used to complete data sharing and data reading authorization.

[0084] based on Figure 1 As shown in the structure, the transcutaneous glucose monitoring system 1 of the present invention includes a continuous glucose monitoring device 2, which has a glucose sensor 21 implanted under the patient's skin and a wireless communication unit (transmitter) 22 for transmitting the glucose signal or data sensed by the glucose sensor (sensor) 21. The patient user terminal 3 is a mobile phone or receiver with a related APP installed, which can provide real-time glucose values, glucose dynamic fluctuation curves and glucose management reports, so that users can more intuitively understand the overall picture of glucose and the reasons for glucose variation, thereby improving lifestyle and health care. In addition, the patient user terminal 3 is wirelessly connected to the cloud server 4 to upload data, and the cloud server 4 provides an authorization mechanism to enable the partner user terminal 5 or the medical care terminal 6 to obtain the patient's glucose concentration data in real time, and conduct remote collaborative care, so as to perform real-time monitoring and emergency response. The cloud server 4 can use encryption mechanisms to ensure the security of data transmission, provide historical data analysis functions, and assist patients and medical personnel in long-term glucose management.

[0085] Furthermore, if Figure 2 As shown, the continuous glucose monitoring device 2 of this embodiment includes:

[0086] A glucose sensor 21 is implanted subcutaneously in a patient to monitor the glucose concentration in the interstitial fluid of the patient's subcutaneous tissue;

[0087] A temperature sensor 23, used to monitor the ambient temperature;

[0088] A glucose measuring unit 24, for applying voltage to the glucose sensor to measure the glucose concentration;

[0089] A battery 26 for power supply;

[0090] A wireless communication unit 22, used for data transmission;

[0091] The memory 27 is used for data storage.

[0092] In another embodiment, the continuous glucose monitoring device 2 also includes an acceleration sensor 25 for detecting the patient's movements or postures, providing motion information and sleep information, and used to determine measurement errors caused by glucose changes and movements or posture changes, thereby improving the accuracy and reliability of the continuous glucose monitoring device 2.

[0093] In this embodiment, based on Figure 2 The continuous glucose monitoring device 2 shown can continuously and dynamically detect glucose changes. During the life cycle of the glucose sensor 21, the frequency of measuring glucose can be every 30 seconds, every minute, every 2 minutes, every 5 minutes, every 10 minutes, every 15 minutes, every 30 minutes, and every hour. Then, the wireless communication unit 22 transmits the glucose signal measured by the glucose sensor 21 (or converts the glucose signal into glucose concentration data according to the design of the transmitter and receiver for signal conversion and sensing functions) to the patient user terminal 3 for display on the user interface. In another embodiment, the glucose sensor 21 can be implanted subcutaneously in combination with a micro-transmitter (not shown).

[0094] Furthermore, if Figure 3 As shown, the patient user terminal 3 of this embodiment includes:

[0095] User interface, used to provide warm-up status display, glucose data display and report analysis functions;

[0096] A wireless communication module 31, for receiving and synchronizing glucose concentration data transmitted by the continuous glucose monitoring device 2;

[0097] Storage 32, for storing glucose concentration data, trend analysis, patient health records and calibration data, etc.;

[0098] One or more processors 33, used to execute various functional instructions;

[0099] A warm-up control unit 34, configured to provide the warm-up progress and completion time of the continuous glucose monitoring device 2 through a processor;

[0100] The glucose data processing unit 35 is used to continuously receive and process glucose concentration data through one or more processors after the warm-up is completed, generate real-time glucose readings, dynamic glucose fluctuation curves and glucose management reports, so that users can understand the glucose change trend and possible influencing factors in real time and comprehensively.

[0101] In this embodiment, the patient client 3 is wirelessly connected to the cloud server 4 to upload data, and the cloud server 4 provides an authorization mechanism to enable the partner client 5 or the medical care client 6 to obtain the patient's glucose concentration data in real time for remote collaborative care, so as to perform real-time monitoring and emergency response. The cloud server 4 can use encryption mechanisms to ensure the security of data transmission, provide historical data analysis functions, and assist patients and medical personnel in long-term glucose management.

[0102] Furthermore, if Figure 4 As shown, the warm-up control unit 34 of this embodiment includes:

[0103] The time setting module 341 is used to enable the one or more processors 33 to provide a warm-up plan completion time for the continuous glucose monitoring device 2 according to the preset warm-up time;

[0104] A response module 342, configured to enable one or more processors 33 to detect a power-on action of the continuous glucose monitoring device 2 and respond;

[0105] The time recording module 343 is used to enable one or more processors 33 to record the power-on time and warm-up time of the continuous glucose monitoring device 2.

[0106] In another embodiment, the warm-up control unit 34 includes:

[0107] A power check module is used to monitor the remaining power of the continuous glucose monitoring device 2 and the patient user terminal 3 and compare it with a preset startup threshold to determine whether to perform the startup and warm-up procedures; when the remaining power of the continuous glucose monitoring device 2 is lower than the startup threshold, the startup process is automatically delayed and a low power warning is provided until the power is sufficient to perform the warm-up procedure;

[0108] The time setting module is used to enable one or more processors 33 to provide a warm-up plan completion time for the continuous glucose monitoring device 2 according to a preset warm-up time.

[0109] Furthermore, the user interface of the patient user terminal 3 of this embodiment includes:

[0110] The note module is used by patients to record medication, diet and exercise conditions, and obtain the patient's user information based on the log records. Figure 5 ;

[0111] Warm-up progress display module, used to display the warm-up progress of the continuous glucose monitoring device, refer to Figure 7 ;

[0112] The glucose display module is used to display the current glucose concentration data and glucose value fluctuations through different types of trend icons in a block-like design.

[0113] like Figure 6 The user interface display diagram of the patient user terminal 3 is shown. The block design of the interface can create a larger sense of space and improve the cleanliness and comfort of the interface. The interface can intuitively present glucose information and help users monitor and analyze glucose change trends in real time for more effective diabetes management. The block design of the GUI enables users to quickly obtain necessary information and further adjust diet, exercise or medication to maintain glucose stability. The GUI mainly includes:

[0114] The top information area is used to provide the remaining days of use of the current continuous glucose monitoring device, real-time glucose values ​​and trend icons, and indicate the glucose status through color changes or icons; for example, when the glucose value is abnormal, the system will use different colors (such as green, orange or red) to remind the user. In addition, this area also displays glucose trend information, indicating whether the current glucose is rising, falling or stable, helping users to respond to glucose changes early. Among them, the trend icon can be selectively replaced by other types of icons. The different colors and directions of the trend icon can quickly highlight different abnormal situations;

[0115] The glucose change chart area is used to graphically present the glucose change trend in the past few hours (such as within 5 hours); the horizontal axis represents time, the vertical axis represents the glucose value, and different colors are used to indicate the glucose range, for example, green represents the normal range, and yellow and red correspond to high blood sugar or low blood sugar states respectively. This chart can help users visualize glucose fluctuations and provide interactive functions, allowing users to click on specific time points to view detailed glucose concentration data and further analyze potential factors affecting glucose changes;

[0116] The daily monitoring record overview chart area is used to display an overview of the patient's daily glucose trends over the past few days (such as 3 days), allowing the patient to quickly understand glucose changes over the past few days, and automatically mark color blocks greater than 180 mg / dL and less than 70 mg / dL, so that the patient can discover the pattern of glucose fluctuations through this area and further adjust diet, exercise or medication plans to optimize glucose control; the daily monitoring record overview chart area is presented in a plurality of daily glucose trend overview frames, and high blood sugar and low blood sugar marking blocks are provided in each daily glucose trend overview chart, so that the user can have an overview of the blood sugar fluctuation status over the past few days and take corresponding measures.

[0117] The TIR (Percent Time in Range) distribution chart area is used to provide statistics on glucose management. The TIR value can show the proportion of time that the patient is within the target glucose range and visualize the time distribution of glucose levels through a color bar chart; for example, green represents glucose in the normal range, and yellow or red represents high or low glucose, respectively. This area helps users assess the stability of their glucose control and make necessary adjustments to reduce the risk of long-term glucose abnormalities;

[0118] The bottom navigation bar is used to provide a variety of function buttons so that patients can quickly access different functions of the application. Among them, the buttons include: glucose concentration data viewing, logging, report generation, and other application functions or setting options. The logging function allows users to record diet, exercise, and insulin usage, providing more complete glucose management information; the report generation function can organize glucose concentration data into charts and reports for users or doctors to analyze. In addition, the buttons of the bottom navigation bar can be customized according to user habits, which can improve the convenience of operation.

[0119] In this embodiment, through an intuitive and easy-to-operate interface, users can quickly obtain and analyze glucose information, making glucose monitoring more accurate and personalized, and helping to improve the efficiency and effectiveness of diabetes management.

[0120] like Figure 7 As shown, the display mode of the warm-up progress display module of this embodiment is: the warm-up time and / or the warm-up plan completion time. Compared with the warm-up countdown mechanism of previous products on the market, this design is a positive expression or a direct display of the warm-up plan completion time, which allows users to more intuitively understand when the warm-up is completed.

[0121] Furthermore, if Figure 8 As shown, the patient user terminal 3 of this embodiment further includes a correction unit 36, and the correction unit 36 ​​includes:

[0122] The blood sugar data collection module 361 is used to receive the blood sugar value after the patient has tested it through a blood sugar tester, which is input by the patient himself or automatically transmitted to the patient user terminal 3;

[0123] The judgment module 362 is used to analyze the validity of the blood glucose data and confirm whether the continuous glucose monitoring device 2 is operating normally;

[0124] The correction module 363 is used to write the blood glucose data into the patient user terminal 3 when the blood glucose data is valid and the continuous glucose monitoring device 2 operates normally.

[0125] In this embodiment, by Figure 8The correction unit 36 ​​provided can correct the real-time collected glucose concentration data according to the blood glucose data obtained by the blood glucose detector to reduce the deviation of continuous glucose monitoring. When the collected blood glucose data is valid and the continuous glucose monitoring device 2 is operating normally, the blood glucose data is written into the patient user terminal 3 as calibration data and stored. The target user can view the historical data at any time. The safe backup of the data can ensure that the blood glucose information will not be lost due to equipment failure, loss or damage. Even if an unexpected situation occurs, the data can be restored or reconstructed.

[0126] In another embodiment, the patient user terminal 3 is combined with a blood glucose detection module to directly perform blood glucose detection and correction without the need for other additional blood glucose detection devices.

[0127] Furthermore, if Fig. 9 As shown, the patient user terminal 3 of this embodiment also includes:

[0128] A drawing module 37, used for drawing a glucose curve and performing TIR index statistics according to the patient's glucose concentration data;

[0129] An adjustment module 38, for correcting the glucose curve and the TIR index according to the glucose concentration data;

[0130] The generation module 39 is used to generate a continuous glucose monitoring standard report and a dynamic glucose map report for the glucose concentration data.

[0131] Furthermore, the glucose curve includes: a single-day glucose curve graph, a multi-day continuous glucose monitoring thumbnail graph, and a multi-day quartile graph.

[0132] Furthermore, the glucose curve and TIR index graph display the patient's glucose status through different colors.

[0133] In this embodiment, by Fig. 9 The patient user terminal 3 shown can analyze the collected glucose concentration data and user information, draw a glucose curve and perform TIR index statistics, which can help the user understand the glucose monitoring status. In this process, the glucose curve and TIR index can be corrected according to the glucose concentration data to obtain more accurate glucose monitoring results, which is helpful for subsequent disease diagnosis and treatment.

[0134] Time In Range (TIR) ​​is an important indicator for measuring glucose control. It can show the percentage of glucose values ​​within the normal range (70-180 mg / dL). The higher the percentage of TIR within the normal range, the better the glucose control. Generally speaking, medicine recommends that TIR should be continuously greater than 70. Clinical empirical studies have also found that for every 10% increase in TIR, glycosylated hemoglobin (HbA1c) decreases by 0.5%. The higher the TIR ratio, the more it will help delay diabetes-related complications, such as retinopathy. In addition, TIR can also provide more information than traditional point data, such as the duration of hyperglycemia and hypoglycemia. Generally speaking, to increase the time percentage of TIR, it is medically recommended to consider reducing the duration of hypoglycemia first, which is a safer approach. In addition, the TIR box sets the patient's user homepage. During the wearing of the continuous glucose monitoring device, it is convenient for users to check TIR at any time to grasp the overall glucose control status. If the standard is not met, they can respond quickly, such as discussing adjustment measures with the care team. If the standard has been met, users can also relax appropriately to avoid excessive tension.

[0135] Furthermore, the patient user terminal 3 of the present embodiment also includes an alarm module, which is used to send alarm information to the patient user terminal 3 when the patient's glucose value deviates from the healthy glucose value range, such as a high blood sugar alarm, an impending hypoglycemia alarm, a hypoglycemia alarm, or even a TIR abnormality alarm, etc., so as to attract the attention of the target user in time; at the same time, the cloud server 4 includes an alarm module, which can send alarm information to the remote caregiver end authorized by the patient.

[0136] Embodiment 2

[0137] The embodiment of the present invention discloses a transcutaneous glucose monitoring system 1, such as Fig.10 As shown, including:

[0138] A partnership establishment module 7 is used to scan the barcode information associated with the continuous glucose monitoring device through a camera for authorization, or send an invitation link to the patient user terminal 3 through a third-party platform (such as LINE, EMail or Messenger) to complete the authentication and authorization of the patient identity and the partner identity;

[0139] Partner client 5 queries glucose concentration data and the patient's basic information, glucose monitoring instructions, medication instructions, and consultation instructions based on the patient's authorization.

[0140] The steps for establishing a partnership through barcode scanning include:

[0141] a). On the partner client 5, click "Add Relationship" and enter the barcode scanning mode;

[0142] b). Operating at the patient user terminal 3 to generate a barcode containing a unique identifier;

[0143] c). Scanning the barcode on the partner client 5 through a camera or barcode scanner, and sending the parsed identifier to the server;

[0144] d). The server verifies the validity of the identifier and returns the basic information of the partner client 5 to the patient client 3;

[0145] e). After confirming the partner information on the patient client 3, click "Confirm to Join" to request the server to establish a data sharing relationship;

[0146] f). The server formally binds the accounts of both parties and allows the patient client 3 to access the continuous glucose monitoring data of the partner client 5;

[0147] g). The server synchronizes data according to predetermined conditions and triggers a notification mechanism to prompt abnormal glucose concentration data or important changes.

[0148] Steps to invite partnerships through third-party platforms include:

[0149] a). Send an invitation request to the server through the patient client 3;

[0150] b). The server generates an exclusive invitation link according to the invitation request, and the invitation link includes a unique identifier;

[0151] c). Scanning the barcode on the patient client 3 through a camera or barcode scanner, and sending the parsed identifier to the server;

[0152] d). Transmitting the invitation link to the partner user terminal 5 through at least one third-party platform on the patient user terminal 3;

[0153] e). Clicking the invitation link on the partner client 5 and transmitting the request to the server;

[0154] f). The server verifies the validity of the unique identifier and prompts the partner client 5 to authenticate and bind an account or create a new account;

[0155] g). After the partner user terminal 5 agrees, the server establishes a data sharing relationship between the patient user terminal 3 and the partner user terminal 5;

[0156] h). The server synchronizes the glucose concentration data of the patient client 3 to the partner client 5 and triggers a notification mechanism according to predetermined conditions.

[0157] This embodiment simplifies the process of establishing a partnership through barcode scanning or invitation from a third-party platform, making account binding faster and improving data security. It uses a unique identifier and server verification mechanism to improve data transmission security. In addition, the system has a real-time notification mechanism. When the patient's glucose concentration data is abnormal, it can automatically send an alert to the partner user terminal 5 to ensure real-time response. In order to improve the flexibility of use, the system allows the partner user terminal 5 to set the data visibility range and access time length, and supports multi-user mode, so that multiple patient user terminals 3 can establish a data sharing relationship with the same partner user terminal 5, improving the convenience and efficiency of remote care.

[0158] Furthermore, in the transcutaneous glucose monitoring system 1 of this embodiment, after receiving the authorization application from the partner user terminal 5 on the patient user terminal 3, the patient selects the data that can be consulted and authorizes it through a digital signature for subsequent data query.

[0159] Furthermore, if Fig.11 , Fig.12 As shown, the partner client 5 of this embodiment includes:

[0160] Early warning module, used to understand the glucose fluctuations of multiple partners and take effective measures in time;

[0161] An update module is used to prioritize the glucose monitoring status of a partner that is updated in real time;

[0162] Glucose display module, used to obtain the current glucose monitoring status of multiple partners and infer the cause of fluctuations through glucose change trends;

[0163] The blood glucose display module is used to obtain the latest blood glucose test records.

[0164] exist Fig.11 In the data, the glucose status of each partner will be sorted according to the time of data update, and the user of the partner user terminal 5 can preferentially see the real-time glucose monitoring status of a partner; among them, the continuous glucose monitoring data can be used to quickly understand the patient's current monitoring status and infer the cause of fluctuations through the previous glucose trend, and the blood glucose data can be used to understand the latest blood glucose record. The partner user terminal 5 of this embodiment combines the blood glucose detector and the continuous glucose monitoring device to monitor the partner's glucose status, and the way to obtain information is more diverse and more accurate.

[0165] like Fig.12Furthermore, the partner user terminal 5 of the present embodiment also includes a note classification module for recording abnormal glucose events and occurrence times, marking abnormal glucose ranges, and converting the marked content to the timeline to compare glucose fluctuations and further infer the causes of glucose fluctuations. Among them, event categories can be distinguished by different colors. After the above-mentioned note classification module converts the marked content to the timeline, the patient and the partner user terminal can intuitively compare the relationship between glucose changes and specific events (such as diet, exercise or stress, etc.), so as to adjust living habits or treatment plans, improve personalized management, and distinguish event categories by different colors, so that users can quickly identify and pay attention to specific types of abnormalities, such as hypoglycemia, hyperglycemia or fluctuations related to specific activities, further improve monitoring efficiency, and identify potential risks in real time. In another implementation, the above-mentioned note classification module can also be set at the patient user terminal 3.

[0166] Furthermore, the partner client 5 of this embodiment includes a glycosylated hemoglobin display module, such as Fig.13 As shown, it is used to correspond the patient's glycated hemoglobin value to the color bar graph, so as to directly confirm the specific segment of the patient's glycated hemoglobin result in the common standard system, visualize the results, reduce the learning cost, and intuitively understand whether the patient's blood sugar control has improved.

[0167] The various embodiments in this specification are described in a progressive manner, and each embodiment focuses on the differences from other embodiments. The same or similar parts between the various embodiments can be referenced to each other.

[0168] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A transcutaneous glucose monitoring system, characterized in that: include: Continuous glucose monitoring devices are used to monitor the glucose concentration in the patient's subcutaneous interstitial fluid; The patient user terminal is used to obtain continuous glucose monitoring device information, receive glucose concentration data, and display the warm-up progress of the continuous glucose monitoring device; Cloud server, used to complete data sharing and authorization to read data; Among them, the user interface of the patient client includes: The top information area is used to provide the remaining days of use of the current continuous glucose monitoring device, real-time glucose values ​​and trend icons, and indicate the glucose status through color changes or icons; Glucose change chart area, used to graphically present the glucose change trend over the past few hours; The daily monitoring record overview chart area is used to display the patient's daily glucose trend overview for the past few days; The TIR distribution chart area is used to provide statistics on glucose management, showing the proportion of time the patient is within the target glucose range and visualizing the temporal distribution of glucose levels through a color bar graph; The bottom navigation bar is used to provide multiple function buttons to allow patients to quickly access different functions of the application.

2. A transcutaneous glucose monitoring system according to claim 1, characterized in that: Continuous glucose monitoring devices include: A glucose sensor is implanted under the patient's skin to monitor the glucose concentration in the patient's subcutaneous interstitial fluid; Temperature sensor, used to monitor ambient temperature; A glucose measuring unit, used for applying voltage to the glucose sensor to measure the glucose concentration; Batteries, for power supply; Wireless communication unit for data transmission.

3. A transcutaneous glucose monitoring system according to claim 1, characterized in that: The patient user end includes: User interface, used to provide warm-up status display, glucose data display and report analysis functions; A wireless communication module, used for receiving glucose concentration data transmitted by a continuous glucose monitoring device; a memory for storing glucose concentration data, trend analysis, patient health records, and calibration data; One or more processors for executing various functional instructions; A warm-up control unit, used for providing the warm-up progress and completion time of the continuous glucose monitoring device through a processor; The glucose data processing unit is used to continuously receive and process glucose concentration data through one or more processors after the warm-up is completed, and generate real-time glucose readings, dynamic glucose fluctuation curves and glucose management reports.

4. A transcutaneous glucose monitoring system according to claim 3, characterized in that: The warm-up control unit includes: A time setting module, configured to cause one or more processors to provide a warm-up plan completion time for the continuous glucose monitoring device according to a preset warm-up time; A response module, configured to enable one or more processors to detect a power-on action of the continuous glucose monitoring device and respond; The time recording module is used to enable one or more processors to record the power-on time and warm-up time of the continuous glucose monitoring device.

5. A transcutaneous glucose monitoring system according to claim 3, characterized in that: The warm-up control unit includes: A power check module, used to monitor the remaining power of the continuous glucose monitoring device and the patient user end and compare it with the preset startup threshold to determine whether to perform the startup and warm-up procedures; The time setting module is used to enable one or more processors to provide a warm-up plan completion time for the continuous glucose monitoring device according to a preset warm-up time.

6. A transcutaneous glucose monitoring system according to claim 1, characterized in that: The patient user end includes: The note module is used by patients to record medication, diet and exercise conditions, and obtain the patient's user information based on the log records; A warm-up progress display module, used to display the warm-up progress of the continuous glucose monitoring device; The glucose display module is used to display the current glucose concentration data and glucose value fluctuations through different types of trend icons in a block-like design.

7. A transcutaneous glucose monitoring system according to claim 6, characterized in that: The warm-up progress display module displays the warm-up time and / or the warm-up plan completion time.

8. The transcutaneous glucose monitoring system according to claim 1, wherein the patient user terminal further comprises a calibration unit, characterized in that: The calibration unit includes: The blood sugar data collection module is used to receive the blood sugar value after the patient has tested it with a blood sugar tester, which is input by the patient himself or automatically transmitted to the patient user terminal; A judgment module is used to analyze the validity of blood glucose data and confirm whether the continuous glucose monitoring device is operating normally; The correction module is used to write the blood glucose data into the patient user terminal when the blood glucose data is valid and the continuous glucose monitoring device is operating normally.

9. A transcutaneous glucose monitoring system according to claim 1, characterized in that: The patient client also includes: A drawing module is used to draw glucose curves and perform TIR index statistics based on the patient's glucose concentration data; An adjustment module, used to correct the glucose curve and TIR index according to the glucose concentration data; The generation module is used to generate a continuous glucose monitoring standard report and a dynamic glucose map report for glucose concentration data.

10. A transcutaneous glucose monitoring system according to claim 9, characterized in that: Glucose curves include: single-day glucose curve graph, multi-day continuous glucose monitoring thumbnails and multi-day quartile graphs.

11. A transcutaneous glucose monitoring system according to claim 9, characterized in that: The glucose curve and TIR indicator graph show the patient's glucose status through different colors.

12. A transcutaneous glucose monitoring system according to claim 1, characterized in that: The patient user terminal also includes an alarm module for sending an alarm message to the patient user terminal when the patient's glucose value deviates from the healthy glucose value range.

13. A transcutaneous glucose monitoring system, characterized in that: include: A partnership establishment module is used to scan the barcode information associated with the continuous glucose monitoring device through a camera for authorization, or send an invitation link to the patient user end through a third-party platform to complete the authentication and authorization of the patient's identity and the partner's identity; The partner user end queries glucose concentration data and the patient's basic information, glucose monitoring instructions, medication instructions, and consultation instructions based on the patient's authorization.

14. A transcutaneous glucose monitoring system according to claim 13, characterized in that: Partner clients include: Early warning module, used to understand the glucose fluctuations of multiple partners and take effective measures in time; An update module is used to prioritize the glucose monitoring status of a partner that is updated in real time; Glucose display module, used to obtain the current glucose monitoring status of multiple partners and infer the cause of fluctuations through glucose change trends; The blood glucose display module is used to obtain the latest blood glucose test records.

15. A transcutaneous glucose monitoring system according to claim 13, characterized in that: The partner user terminal also includes a note classification module for recording abnormal glucose events and their occurrence time, marking the abnormal glucose range, and converting the marked content to the timeline to compare the glucose fluctuations and further infer the causes of the glucose fluctuations.

16. A transcutaneous glucose monitoring system according to claim 13, characterized in that: The partner client includes a glycated hemoglobin display module for mapping the glycated hemoglobin value of the patient to a color bar graph, so as to directly confirm the specific section where the glycated hemoglobin result of the patient is located in the common standard system.

Images